CLTX / Celsus Therapeutics - Pengajuan SECLaporan Tahunan, Pernyataan Proksi

REGISTRATION RIGHTS AGREEMENT

Exhibit 10.2 REGISTRATION RIGHTS AGREEMENT This Registration Rights Agreement (this “Agreement”) is entered into effective as August 29, 2025 (the “Execution Date”), by and between Akari Therapeutics, Plc, a public limited company incorporated under the laws of England and Wales (the “Company”), and White Lion Capital, LLC, a Nevada limited liability company (the “Investor”). RECITALS A. WHEREAS,

Calculation of Filing Fee Tables Form S-1 (Form Type) AKARI THERAPEUTICS PLC (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered

Exhibit 107 Calculation of Filing Fee Tables Form S-1 (Form Type) AKARI THERAPEUTICS PLC (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Security Type Security Class Title Fee Calculation Rule Amount Registered (1) Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price (2) (3) Fee Rate Amount of Registration Fee Equity American Depositary Shares (“ADSs”), each representing 2,000 Ordinary Shares, $0.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 28, 2025 Akari Therapeutic

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 28, 2025 Akari Therapeutics, Plc (Exact Name of Registrant as Specified in Charter) England and Wales 001-36288 98-1034922 (State or other jurisdiction of incorporation) (Commi

ORDINARY SHARE PURCHASE AGREEMENT

Exhibit 10.3 ORDINARY SHARE PURCHASE AGREEMENT This Ordinary Share Purchase Agreement (this “Agreement”) is entered into effective as August 29, 2025 (the “Execution Date”), by and between Akari Therapeutics, Plc, public limited company incorporated under the laws of England and Wales (the “Company”), and White Lion Capital, LLC, a Nevada limited liability company (the “Investor”). WHEREAS, the pa

As filed with the Securities and Exchange Commission on August 29, 2025

As filed with the Securities and Exchange Commission on August 29, 2025 Registration No.

REGISTRATION RIGHTS AGREEMENT

Exhibit 10.4 REGISTRATION RIGHTS AGREEMENT This Registration Rights Agreement (this “Agreement”) is entered into effective as August 29, 2025 (the “Execution Date”), by and between Akari Therapeutics, Plc, a public limited company incorporated under the laws of England and Wales (the “Company”), and White Lion Capital, LLC, a Nevada limited liability company (the “Investor”). RECITALS A. WHEREAS,

ORDINARY SHARE PURCHASE AGREEMENT

Exhibit 10.1 ORDINARY SHARE PURCHASE AGREEMENT This Ordinary Share Purchase Agreement (this “Agreement”) is entered into effective as August 29, 2025 (the “Execution Date”), by and between Akari Therapeutics, Plc, public limited company incorporated under the laws of England and Wales (the “Company”), and White Lion Capital, LLC, a Nevada limited liability company (the “Investor”). WHEREAS, the pa

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 15, 2025 Akari Therapeutic

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 15, 2025 Akari Therapeutics, Plc (Exact Name of Registrant as Specified in Charter) England and Wales 001-36288 98-1034922 (State or other jurisdiction of incorporation) (Commi

LOAN CANCELLATION AND EXCHANGE AGREEMENT

Exhibit 10.1 LOAN CANCELLATION AND EXCHANGE AGREEMENT This LOAN CANCELLATION AND EXCHANGE AGREEMENT (this “Agreement”) is entered into as of August 7, 2025 (the “Effective Date”) by and among DR. HOYOUNG HUH, an individual (“Dr. Huh”), AKARI THERAPEUTICS, PLC, a public company limited by shares incorporated in England and Wales (the “Company”), and PEAK BIO INC, a Delaware corporation and wholly-o

EX-99.1

Exhibit 99.1

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 19, 2025 Akari Therapeutic

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 19, 2025 Akari Therapeutics, Plc (Exact Name of Registrant as Specified in Charter) England and Wales 001-36288 98-1034922 (State or other jurisdiction of incorporation) (Commi

Form of 20% Original Issue Discount Promissory Note.

Exhibit 10.3 20% ORIGINAL ISSUE DISCOUNT PROMISSORY NOTE THIS NOTE HAS NOT BEEN REGISTERED UNDER THE UNITED STATES SECURITIES ACT OF 1933, AS AMENDED, OR UNDER THE SECURITIES LAWS OF ANY STATE OR OTHER JURISDICTION, AND MAY NOT BE SOLD, ASSIGNED, TRANSFERRED, PLEDGED OR OTHERWISE DISPOSED OF EXCEPT IN COMPLIANCE WITH, OR PURSUANT TO AN EXEMPTION FROM, THE REQUIREMENTS OF SUCH ACT OR SUCH LAWS. AKA

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-36288 Akari Thera

Form of Amendment No. 1 to Series A Warrant.

Exhibit 10.4 August [●], 2025 AMENDMENT NO. 1 TO SERIES A WARRANT This Amendment No. 1 (this “Amendment”) to the Series A Warrant (as defined below), is made by and between Akari Therapeutics, Plc, a public company with limited liability incorporated under the laws of England and Wales (the “Company”), and (the “Holder”). WHEREAS, the Holder is the holder of outstanding Series A Warrant to purchas

Form of August 2025 Note Purchase Agreement.

Exhibit 10.2 NOTE PURCHASE AGREEMENT This Note Purchase Agreement (this “Agreement”), dated as of August [●], 2025, is entered into by and between Akari Therapeutics, Plc, a public company with limited liability incorporated under the laws of England and Wales (the “Company”), and the buyer set forth on the signature page(s) hereto (the “Buyer”). RECITALS On the terms and subject to the conditions

Filing Fee Table

Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Akari Therapeutics, PLC (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities and Carry Forward Securities Security Type Security Class Title Fee Calculation Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Carry Forward Form Type Carry Forward File Number Carry Forward Initial effective date Filing Fee Previously Paid In Connection with Unsold Securities to be Carried Forward Newly Registered Securities Fees to Be Paid Equity Ordinary shares, par value $0.

As filed with the Securities and Exchange Commission on July 29, 2025.

As filed with the Securities and Exchange Commission on July 29, 2025. Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Form S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 AKARI THERAPEUTICS, PLC (Exact Name of Registrant as Specified in its Charter) England and Wales 98-1034922 (State or other jurisdiction of incorporation or organization)

Filing Fee Table

Exhibit 107 EX-FILING FEES Calculation of Filing Fee Tables Form S-8 (Form Type) Akari Therapeutics, Plc (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Fees Previously Paid Security Type Security Class Title(1) Fee Calculation Rule Amount Registered(2) Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Ordinary Shares, par value $0.

As filed with the Securities and Exchange Commission on July 29, 2025

As filed with the Securities and Exchange Commission on July 29, 2025 Registration No.

Amendment No. 2 to the Akari Therapeutics, PLC 2023 Equity Incentive Plan

Exhibit 10.1 AMENDMENT NO. 2 TO THE AKARI THERAPEUTICS, PLC 2023 EQUITY INCENTIVE PLAN WHEREAS, Akari Therapeutics, plc (the “Company”) maintains the Akari Therapeutics, plc 2023 Equity Incentive Plan (the “Plan”) which was previously adopted by the Board of Directors of the Company (the “Board”) and approved by the Company’s shareholders; WHEREAS, the Board believes that the number of shares of C

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits, Submission of Matters to a Vote of Security Holders

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 30, 2025 Akari Therapeutics, Plc (Exact Name of Registrant as Specified in Charter) England and Wales 001-36288 98-1034922 (State or other jurisdiction of incorporation) (Commiss

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(A) OF THE SECURITIES EXCHANGE ACT OF 1934 (AMENDMENT NO. )

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(A) OF THE SECURITIES EXCHANGE ACT OF 1934 (AMENDMENT NO. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Defin

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(A) OF THE SECURITIES EXCHANGE ACT OF 1934 (AMENDMENT NO. )

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(A) OF THE SECURITIES EXCHANGE ACT OF 1934 (AMENDMENT NO. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defin

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 15, 2025 Akari Therapeutics, Plc (Exact Name of Registrant as Specified in Charter) England and Wales 001-36288 98-1034922 (State or other jurisdiction of incorporation) (Commissi

Akari Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update Advancing development of novel Antibody Drug Conjugates (ADCs) with immuno-oncology payloads to treat multiple cancer tumors Rounding out executive team wit

Akari Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update Advancing development of novel Antibody Drug Conjugates (ADCs) with immuno-oncology payloads to treat multiple cancer tumors Rounding out executive team with deep oncology experience by appointing new Head of Business Development - Oncology BOSTON and LONDON – May 15, 2025 – Akari Therapeutics, Plc (Nasdaq: AKTX), a biotechnology company developing novel Antibody Drug Conjugates (ADCs) with immuno-oncology payloads for the treatment of cancer, today reported its financial results for the first quarter ended March 31, 2025 and provided a corporate update.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-36288 Akari Ther

AKARI THERAPEUTICS, PLC 51,770,782,000 Ordinary Shares Represented by 25,885,391 American Depositary Shares

Filed pursuant to Rule 424(b)(3) Registration Statement No. 333-287012 PROSPECTUS AKARI THERAPEUTICS, PLC 51,770,782,000 Ordinary Shares Represented by 25,885,391 American Depositary Shares This prospectus relates to the resale, by the selling shareholders identified in this prospectus, of up to an aggregate of 25,885,391 American Depositary Shares, or ADSs, representing up to an aggregate of 51,7

Chief Executive Officer Agreement, dated as of March 13, 2025, by and between the Company and Abizer Gaslightwala.

March 13, 2025 Abizer Gaslightwala Re: Offer of Employment by Akari Therapeutics, Plc Dear Abizer: On behalf of Akari Therapeutics, Plc (the “Company”), I am pleased to confirm our offer to employ you as Chief Executive Officer.

Akari Therapeutics, Plc 22 Boston Wharf Road, FL 7 Boston, MA 02210 May 12, 2025

Akari Therapeutics, Plc 22 Boston Wharf Road, FL 7 Boston, MA 02210 May 12, 2025 VIA EDGAR U.

Prospectus Summary Risk Factors Note Regarding Forward Looking Statements Use of Proceeds Unaudited Pro Forma Condensed Combined Financial Information NOTES TO UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION Note 1. Transaction Accountin

As filed with the Securities and Exchange Commission on May 6, 2025 Registration No.

Filing Fee Table

Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Akari Therapeutics, Plc (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule or Carry Forward Rule Amount Registered(2) Proposed Maximum Offering Price Per Share Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee (2)(3) Equity Ordinary Shares, $0.

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 16, 2025 Akari Therapeutics, Plc (Exact Name of Registrant as Specified in Charter) England and Wales 001-36288 98-1034922 (State or other jurisdiction of incorporation) (Commis

Akari Therapeutics Reports Full Year 2024 Financial Results and Provides Corporate Update Advancing development of next-generation precision Antibody Drug Conjugates (ADCs) to address multiple indications across a range of cancer types Continued prog

Exhibit 99.1 Akari Therapeutics Reports Full Year 2024 Financial Results and Provides Corporate Update Advancing development of next-generation precision Antibody Drug Conjugates (ADCs) to address multiple indications across a range of cancer types Continued progress of lead program, AKTX-101, for the treatment of solid tumors Platform technology to fuel pipeline with ability to generate novel ADC

Consulting Agreement between the Company and Wendy F. DiCicco dated January 15, 2024.

Exhibit 10.28 CONSULTING SERVICES AGREEMENT This Consulting Services Agreement ("Agreement") is entered into as of January 15, 2024 ("Effective Date") by and between Board Advantage LLC, with an address of 948 Drovers Lane, Chester Springs, PA 19425 ("Consultant"), and Akari Therapeutics, Inc. located at 22 Boston Wharf Road FL 7, Boston, MA 02210 ("Akari"). Consultant and Akari are each referred

Exhibit 4.7

Exhibit 4.7 DESCRIPTION OF SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED The following description is a summary of the material terms of Akari Therapeutics, Plc’s (the “Company”) ordinary shares with a par value $0.0001 per share and American Depositary Shares (the “ADSs”), each representing 2,000 ordinary shares. This description also summarizes r

10-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-36288 Akari Therapeut

Amendment No. 1 to Consulting Agreement between the Company and Wendy DiCicco dated September 1, 2023.

Exhibit 10.27 AMENDMENT NO. 1 TO CONSULTING SERVICES AGREEMENT This Amendment No. 1 (“Amendment”) is entered into as of September 1, 2023 ("Effective Date") by and between Board Advantage LLC, with an address of 948 Drovers Lane, Chester Springs, PA 19425 ("Consultant"), and Akari Therapeutics, Inc. located at 22 Boston Wharf Road, Fl 7, Boston, MA 02210 ("Akari"), and amends the Consulting Agreem

List of Subsidiaries.

Exhibit 21.1 Subsidiaries of Akari Therapeutics, Plc The following table sets forth the name and jurisdiction of incorporation of our subsidiaries: Name of Subsidiary Jurisdiction of Incorporation Celsus Therapeutics Inc. Delaware Morria Biopharma Ltd. Israel Volution Immuno Pharmaceuticals SA Switzerland Akari Malta Limited Malta Peak Bio Inc. Delaware Peak Bio Co., Ltd. Republic of Korea Ignyte

Clawback Policy.

Exhibit 97 Akari Therapeutics, Plc Executive Officer Clawback Policy Approved by the Board of Directors on November 27, 2023 (the “Adoption Date”) I.

Restricted Stock Unit Agreement between the Company and Rachelle Jacques dated June 1, 2023.

Exhibit 10.25 AKARI THERAPEUTICS, PLC 2023 EQUITY INCENTIVE PLAN RESTRICTED STOCK UNIT AGREEMENT PARTICIPANT: Rachelle Jacques NUMBER OF RSUs: 218,055,800 DATE OF GRANT: June 30, 2023 Akari Therapeutics, Plc, a public limited company formed under the laws of England and Wales (the “Company”), is pleased to confirm that the Participant has been granted a Restricted Stock Unit Award (this “Award”),

Insider Trading Policy.

AKARI THERAPEUTICS PLC INSIDER TRADING POLICY Akari Therapeutics, Plc (the “Company”) has adopted the following policy regarding trading by Company personnel in the Company’s securities (the “Insider Trading Policy,” or this “Policy”).

Consulting Agreement between the Company and Wendy DiCicco dated July 17, 2023.

Exhibit 10.26 CONSULTING SERVICES AGREEMENT This Consulting Services Agreement ("Agreement") isentered into as of July 17, 2023 ("Effective Date") by and between Board Advantage LLC, with an address of 948 Drovers Lane, Chester Springs, PA 19425 ("Consultant"), and Akari Therapeutics, Inc. located at 1460 Broadway, New York, NY 10036 ("Akari"). Consultant and Akari are each referredto individually

Separation Agreement, dated August 18, 2024, by and between Akari Therapeutics, Plc and Rachelle Jacques.

Exhibit 10.40 CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS BOTH NOT MATERIAL AND IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. INFORMATION THAT WAS OMITTED HAS BEEN NOTED IN THIS DOCUMENT WITH A PLACEHOLDER IDENTIFIED BY THE MARK “[***]”. August 18, 2024 PERSONAL AND CONFIDENTIAL Rachelle Jacques [***] Re: Separation Agreement Dear Rachelle,

Stock Option Agreement between the Company and Wendy F. DiCicco dated July 17, 2023.

Exhibit 10.29 STOCK OPTION AGREEMENT United States Participants (NSO) AGREEMENT made as of the date of the grant set forth in Exhibit A (the “Effective Date”) by and between Akari Therapeutics, Plc, a company formed under the laws of England and Wales, and having a place of business at 22 Boston Wharf Road, Floor 7, Boston, MA 02210, USA (the “Company”) and the individual whose name and address ap

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING SEC FILE NUMBER 001-36288 CUSIP NUMBER 00972G207 (Check One): ☒ Form 10-K ☐ Form 20-F ☐ Form 11-K ☐ Form 10-Q ☐ Form 10-D ☐ Form N-CEN ☐ Form N-CSR For Period Ended: December 31, 2024 ☐ Transition Report on Form 10-K ☐ Transition Report on Form 20-F ☐ Transition Report on Form 11-K ☐ Tra

Chief Executive Officer Letter Agreement dated as of March 18, 2025, by and between the Company and Abizer Gaslightwala

March 18, 2025 Abizer Gaslightwala Re: Clarifications for the Offer of Employment by Akari Therapeutics, Plc Dear Abizer: Please accept this letter of clarification to your Offer of Employment by Akari Therapeutics, Plc dated March 13, 2025, and fully executed as of March 17, 2025 (the “Agreement”).

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 14, 2025 Akari Therapeutics, Plc (Exact Name of Registrant as Specified in Charter) England and Wales 001-36288 98-1034922 (State or other jurisdiction of incorporation) (Commis

[Signature page follows.]

March 13, 2025 Abizer Gaslightwala Re: Offer of Employment by Akari Therapeutics, Plc Dear Abizer: On behalf of Akari Therapeutics, Plc (the “Company”), I am pleased to confirm our offer to employ you as Chief Executive Officer.

Form of Series A Warrant issued by Akari Therapeutics, Plc in connection with the March Private Placement (incorporated by reference to Exhibit 4.2 previously filed with the Registrant’s Current Report on Form 8-K as filed with the SEC on March 3, 2025).

Exhibit 4.2 NEITHER THIS SECURITY NOR THE SECURITIES INTO WHICH THIS SECURITY IS EXERCISABLE HAS BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR

Form of Securities Purchase Agreement dated as of March 2, 2025 between Akari Therapeutics, Plc and the purchasers party thereto (incorporated by reference to Exhibit 10.1 previously filed with the Registrant’s Current Report on Form 8-K as filed with the SEC on March 3, 2025).

Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of March 2, 2025 between Akari Therapeutics, Plc, a public company with limited liability incorporated under the laws of England and Wales (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively

Form of Series B Warrant issued by Akari Therapeutics, Plc in connection with the March Private Placement (incorporated by reference to Exhibit 4.3 previously filed with the Registrant’s Current Report on Form 8-K as filed with the SEC on March 3, 2025).

Exhibit 4.3 Series B Warrant NEITHER THIS SECURITY NOR THE SECURITIES INTO WHICH THIS SECURITY IS EXERCISABLE HAS BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN

Entry into a Material Definitive Agreement

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): March 2, 2025 Akari Therapeutics, Plc (Exact Name of Registrant as Specified in Charter) England and Wales 001-36288 98-1034922 (State or other jurisdiction of incorporation) (Commiss

Form of Pre-Funded Warrant issued by Akari Therapeutics, Plc in connection with the March Private Placement (incorporated by reference to Exhibit 4.1 previously filed with the Registrant’s Current Report on Form 8-K as filed with the SEC on March 3, 2025).

Exhibit 4.1 NEITHER THIS SECURITY NOR THE SECURITIES INTO WHICH THIS SECURITY IS EXERCISABLE HAS BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR

Regulation FD Disclosure, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 13, 2025 Akari Therapeutics, Plc (Exact Name of Registrant as Specified in Charter) England and Wales 001-36288 98-1034922 (State or other jurisdiction of incorporation) (Comm

Corporate Presentation January 2025 NASDAQ: AKTX akaritx.com Next-Generation Precision Bi-Functional Antibody Drug Conjugates

Corporate Presentation January 2025 NASDAQ: AKTX akaritx.com Next-Generation Precision Bi-Functional Antibody Drug Conjugates Forward-Looking Statements This presentation includes expressed or implied forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the Exchange Act), about th

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 12, 2024 Akari Therapeutics, Plc (Exact Name of Registrant as Specified in Charter) England and Wales 001-36288 98-1034922 (State or other jurisdiction of incorporation) (Com

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 12, 2024 Akari Therapeutics, Plc (Exact Name of Registrant as Specified in Charter) England and Wales 001-36288 98-1034922 (State or other jurisdiction of incorporation) (Com

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 6, 2024 Akari Therapeutics, Plc (Exact Name of Registrant as Specified in Charter) England and Wales 001-36288 98-1034922 (State or other jurisdiction of incorporation) (Comm

AKTX / Akari Therapeutics, Plc - Depositary Receipt (Common Stock) / Patel Samir Rashmikant - AMENDMENT NO. 1 TO SCHEDULE 13D Activist Investment

SC 13D/A 1 ea0223686-13da1patelakari.htm AMENDMENT NO. 1 TO SCHEDULE 13D UNITED STATES SECURITIES AND EXCHANGE COMMISSION, Washington, D.C. 20549 SCHEDULE 13D (Amendment No. 1) Under the Securities Exchange Act of 1934 Akari Therapeutics, PLC (Name of Issuer) Ordinary Shares, par value $0.0001 per share (represented by American Depositary Shares) (Title of Class of Securities) 00972G207 (CUSIP Num

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-36288 Akari

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING SEC FILE NUMBER 001-39290 CUSIP NUMBER 97382D 501 (Check One): ☐ Form 10-K ☐ Form 20-F ☐ Form 11-K ☒ Form 10-Q ☐ Form 10-D ☐ Form N-CEN ☐ Form N-CSR For Period Ended: September 30, 2024 ☐ Transition Report on Form 10-K ☐ Transition Report on Form 20-F ☐ Transition Report on Form 11-K ☐ T

UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL STATEMENTS

Exhibit 99.2 UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL STATEMENTS Merger with Peak Bio On March 4, 2024, Akari Therapeutics, Plc (“Akari”) entered into an Agreement and Plan of Merger with Peak Bio and Pegasus Merger Sub, Inc., a Delaware corporation and a wholly-owned subsidiary of Akari (“Pegasus Merger Sub”), as amended by that certain side letter dated August 15, 2024 (the “Merger Agree

Akari Therapeutics Announces Successful Completion of Merger of Akari Therapeutics and Peak Bio - Secures $3.2m in PIPE Financing - - $50m Term Sheet Obtained for Available Financing under Equity Line of Credit -

Exhibit 99.1 Akari Therapeutics Announces Successful Completion of Merger of Akari Therapeutics and Peak Bio - Secures $3.2m in PIPE Financing - - $50m Term Sheet Obtained for Available Financing under Equity Line of Credit - BOSTON and LONDON, November 14, 2024 (GLOBE NEWSWIRE) – Akari Therapeutics, Plc (Nasdaq: AKTX) announces the completion of the merger (the Merger) of Akari Therapeutics, Plc

Form of Securities Purchase Agreement dated as of November 13, 2024 between Akari Therapeutics, Plc and the purchasers party thereto (incorporated by reference to Exhibit 10.1 previously filed with the Registrant’s Current Report on Form 8-K as filed with the SEC on November 14, 2024).

Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of November 13, 2024 between Akari Therapeutics, Plc, a public company with limited liability incorporated under the laws of England and Wales (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collecti

Form of Series D Warrant issued by Akari Therapeutics, Plc in connection with the November Private Placement (incorporated by reference to Exhibit 4.1 previously filed with the Registrant’s Current Report on Form 8-K as filed with the SEC on November 14, 2024).

Exhibit 4.1 NEITHER THIS SECURITY NOR THE SECURITIES INTO WHICH THIS SECURITY IS EXERCISABLE HAS BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR

Regulation FD Disclosure, Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Financial Statements and Exhibits, Completion of Acquisition or Disposition of Assets

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 13, 2024 Akari Therapeutics, Plc (Exact Name of Registrant as Specified in Charter) England and Wales 001-36288 98-1034922 (State or other jurisdiction of incorporation) (Com

Akari Therapeutics Announces Shareholder Approval in Connection With Peak Bio Inc. Merger

Exhibit 99.1 Akari Therapeutics Announces Shareholder Approval in Connection With Peak Bio Inc. Merger BOSTON and LONDON, November 8, 2024 (GLOBE NEWSWIRE) – Akari Therapeutics, Plc (Nasdaq: AKTX), an innovative biotechnology company developing advanced therapies for autoimmune and inflammatory diseases, announces shareholder approval in connection with the merger of Akari Therapeutics, Plc (the C

Regulation FD Disclosure, Financial Statements and Exhibits, Submission of Matters to a Vote of Security Holders

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 7, 2024 Akari Therapeutics, Plc (Exact Name of Registrant as Specified in Charter) England and Wales 001-36288 98-1034922 (State or other jurisdiction of incorporation) (Comm

Akari Therapeutics Announces Effectiveness of Form S-4 and General Meeting Date of November 7, 2024 Related to Peak Bio Merger

Akari Therapeutics Announces Effectiveness of Form S-4 and General Meeting Date of November 7, 2024 Related to Peak Bio Merger BOSTON and LONDON, October 14, 2024 (GLOBE NEWSWIRE) – Akari Therapeutics, Plc (Nasdaq: AKTX), an innovative biotechnology company developing advanced therapies for autoimmune and inflammatory diseases, announces the effectiveness of the Form S-4, originally filed with the SEC on September 13, 2024 related to the merger of Akari Therapeutics, Plc (the Company) and Peak Bio, Inc.

MERGER PROPOSED - YOUR VOTE IS VERY IMPORTANT Akari Therapeutics, Plc Registered office: Highdown House Yeoman Way, Worthing, West Sussex, BN99 3HH, United Kingdom Incorporated in England & Wales with registered no. 05252842

Table of Contents Filed Pursuant to Rule 424(b)(3) Registration No. 333-282127 MERGER PROPOSED - YOUR VOTE IS VERY IMPORTANT Akari Therapeutics, Plc Registered office: Highdown House Yeoman Way, Worthing, West Sussex, BN99 3HH, United Kingdom Incorporated in England & Wales with registered no. 05252842 October 11, 2024 Dear Akari Therapeutics, Plc Shareholder: This letter, the notice of the genera

Filing Fee Table.

Exhibit 107 Calculation of Filing Fee Tables Form S-4 (Form Type) Akari Therapeutics, Plc (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Share Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Carry  Forward  Form  Type  Carry  Forward  File  Number  Carry  Forward  Initial  effective  date  Filing Fee Previously Paid In Connection with Unsold Securities to be Carried Forward Newly Registered Securities Fees to Be  Paid  Equity  Ordinary shares,  $0.

As filed with the Securities and Exchange Commission on October 9, 2024 Registration No. 333-282127 UNITED STATES SECURITIES AND EXCHANGE CO M MIS S IO N WASHINGTON, D.C. 20549 Amendment No. 2 to FORM S-4 REGISTRATION STATEMENT UNDER THE SECURITI ES

Table of Contents As filed with the Securities and Exchange Commission on October 9, 2024 Registration No.

Amendment No. 1 to Consulting Agreement between the Registrant and Wendy F. DiCicco, dated April 26, 2024.

Exhibit 10.27 AMENDMENT NO. 1 TO CONSULTING SERVICES AGREEMENT This Amendment No. 1 (“Amendment”) is entered into as of April 26, 2024 (“Effective Date”) by and between Board Advantage LLC, with an address of 948 Drovers Lane, Chester Springs, PA 19425 (“Consultant”), and Akari Therapeutics, Inc. located at 22 Boston Wharf Road, Fl 7, Boston, MA 02210 (“Akari”), and amends the Consulting Services

[Signature page follows]

CORRESP October 9, 2024 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N.E. Washington, D.C. 20549 Attention: Joshua Gorsky Re: Akari Therapeutics, Plc   Registration Statement on Form S-4   File No. 333-282127 Dear Mr. Gorsky: In accordance with Rule 461 of the General Rules and Regulations under the Securities Act of 1933,

Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 1, 2024 Akari Therapeutics, Plc (Exact Name of Registrant as Specified in Charter) England and Wales 001-36288 98-1034922 (State or other jurisdiction of incorporation) (Commi

As filed with the Securities and Exchange Commission on September 27, 2024 Registration No. 333-282127 UNITED STATES SECURITIES AND EXCHANGE CO M MIS S IO N WASHINGTON, D.C. 20549 Amendment No. 1 to FORM S-4 REGISTRATION STATEMENT UNDER THE SECURITI

Table of Contents As filed with the Securities and Exchange Commission on September 27, 2024 Registration No.

Goodwin Procter LLP

CORRESP Goodwin Procter LLP One Commerce Square 2005 Market Street, 32nd Floor Philadelphia, PA 19103 goodwinlaw.

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 13, 2024 Akari Therapeutics, Plc (Exact Name of Registrant as Specified in Charter) England and Wales 001-36288 98-1034922 (State or other jurisdiction of incorporation) (Co

BUSINESS OF AKARI

Exhibit 99.1 BUSINESS OF AKARI Overview Akari is a biotechnology company focused on developing advanced therapies for autoimmune and inflammatory diseases involving the complement component 5 (“C5”) and leukotriene B4 (“LTB4”) pathways. Each of these pathways has scientifically well-supported causative roles in the diseases we are targeting. Akari believes that blocking these two early mediators o

Amendment to Interim Chief Executive Officer Agreement, between Akari Therapeutics, Plc and Samir R. Patel, M.D., dated as of September 16, 2024

Exhibit 10.1 AMENDMENT TO INTERIM CHIEF EXECUTIVE OFFICER AGREEMENT This Amendment (this “Amendment”) to the Interim Chief Executive Officer Agreement (the “Interim CEO Agreement”), effective May 1, 2024, between Samir R. Patel, M.D. (“Interim CEO”) and Akari Therapeutics, Plc (the “Company”) is effective as of July 1, 2024. All capitalized terms used herein but not otherwise defined shall have th

AKARI THERAPEUTICS, PLC 21,564,862,000 Ordinary Shares Represented by 10,782,431 American Depositary Shares

424B5 Table of Contents Filed pursuant to Rule 424(b)(5) Registration Statement No.

As filed with the Securities and Exchange Commission on September 13, 2024 Registration No. 333-[ ] UNITED STATES SECURITIES AND EXCHANGE COMMISS IO N WASHINGTON, D.C. 20549 FORM S-4 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 AKARI THERA

As filed with the Securities and Exchange Commission on September 13, 2024 Registration No.

Consent of Robert Bazemore

Exhibit 99.4 Consent of Person Named as About to Become Director September 13, 2024 Pursuant to Rule 438 promulgated under the Securities Act of 1933, as amended, I hereby consent to my being named in the Registration Statement on Form S-4 of Akari Therapeutics, Plc, and all amendments thereto (the “Registration Statement”), and any related prospectus filed pursuant to Rule 424 promulgated under t

Amendment to Interim Chief Executive Officer Agreement, dated as of September 13, 2024, by and between the Registrant and Samir Patel, M.D.

Exhibit 10.35 AMENDMENT TO INTERIM CHIEF EXECUTIVE OFFICER AGREEMENT This Amendment (this “Amendment”) to the Interim Chief Executive Officer Agreement (the “Interim CEO Agreement”), effective May 1, 2024, between Samir R. Patel, M.D. (“Interim CEO”) and Akari Therapeutics, Plc (the “Company”) is effective as of July 1, 2024. All capitalized terms used herein but not otherwise defined shall have t

Consent of Hoyoung Huh, MD, PhD

Exhibit 99.1 Consent of Person Named as About to Become Director September 13, 2024 Pursuant to Rule 438 promulgated under the Securities Act of 1933, as amended, I hereby consent to my being named in the Registration Statement on Form S-4 of Akari Therapeutics, Plc, and all amendments thereto (the “Registration Statement”), and any related prospectus filed pursuant to Rule 424 promulgated under t

Filing Fee Table.

Exhibit 107 Calculation of Filing Fee Tables Form S-4 (Form Type) Akari Therapeutics, Plc (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered (2) Proposed Maximum Offering Price Per Share (3) Maximum Aggregate Offering Price (3) Fee Rate Amount of Registration Fee (4) Carry Forward Form Type Carry Forward File Number Carry Forward Initial effective date Filing Fee Previously Paid In Connection with Unsold Securities to be Carried Forward Newly Registered Securities Fees to Be Paid Equity  Ordinary shares, $0.

Consent of Sandip Patel

Exhibit 99.3 Consent of Person Named as About to Become Director September 13, 2024 Pursuant to Rule 438 promulgated under the Securities Act of 1933, as amended, I hereby consent to my being named in the Registration Statement on Form S-4 of Akari Therapeutics, Plc, and all amendments thereto (the “Registration Statement”), and any related prospectus filed pursuant to Rule 424 promulgated under t

Consent of James Neal, MS, MBA

Exhibit 99.2 Consent of Person Named as About to Become Director September 13, 2024 Pursuant to Rule 438 promulgated under the Securities Act of 1933, as amended, I hereby consent to my being named in the Registration Statement on Form S-4 of Akari Therapeutics, Plc, and all amendments thereto (the “Registration Statement”), and any related prospectus filed pursuant to Rule 424 promulgated under t

Akari Therapeutics, Plc 22 Boston Wharf Road, FL 7 Boston, MA 02210 September 11, 2024

Akari Therapeutics, Plc 22 Boston Wharf Road, FL 7 Boston, MA 02210 September 11, 2024 VIA EDGAR U.

As filed with the Securities and Exchange Commission on September 6, 2024

Table of Contents As filed with the Securities and Exchange Commission on September 6, 2024 Registration No.

Form of Securities Purchase Agreement dated as of December 27, 2023 between Akari Therapeutics, Plc and the purchasers party thereto entered into in connection with the December Private Placement.

Exhibit 10.3 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of December 27, 2023, between Akari Therapeutics, Plc, a public company with limited liability incorporated under the laws of England and Wales (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collect

PEAK BIO, INC. CONDENSED CONSOLIDATED BALANCE SHEETS

Exhibit 99.2 PEAK BIO, INC. CONDENSED CONSOLIDATED BALANCE SHEETS June 30 December 31 2024 2023 (Unaudited) Assets Current assets Cash $ 235,774 $ 381,649 Prepaid expenses and other current assets 1,095,939 1,992,458 Total current assets 1,331,713 2,374,107 Property and equipment, net 31,807 153,108 Restricted cash 60,000 60,000 Other noncurrent assets 11,136 9,200 Total assets $ 1,434,656 $ 2,596

Form of Placement Agent Warrant issued by Akari Therapeutics, Plc in connection with the March Private Placement.

Exhibit 4.9 THE SECURITIES REPRESENTED HEREBY HAVE NOT BEEN REGISTERED UNDER THE U.S. SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”) AND ARE “RESTRICTED SECURITIES” AS DEFINED IN RULE 144 PROMULGATED UNDER THE ACT. THE SECURITIES MAY NOT BE OFFERED, SOLD, PLEDGED, OR OTHERWISE DISTRIBUTED OR TRANSFERRED EXCEPT (i) PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE ACT OR (ii) PURSUANT TO AN

AKARI THERAPEUTICS, PLC UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL STATEMENTS

Exhibit 99.3 AKARI THERAPEUTICS, PLC UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL STATEMENTS On March 4, 2024, Akari Therapeutics, Plc, a public company limited, with shares incorporated in England and Wales (“Akari”), and Pegasus Merger Sub, Inc., a Delaware corporation and a wholly-owned subsidiary of Akari (“Merger Sub”), entered into a definitive agreement to acquire Peak Bio Inc., a Delaw

Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 6, 2024 Akari Therapeutics, Plc (Exact Name of Registrant as Specified in Charter) England and Wales 001-36288 98-1034922 (State or other jurisdiction of incorporation) (Com

Filing Fee Table

Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Akari Therapeutics, Plc (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security   Type  Security Class Title Fee Calculation Rule or Carry Forward Rule Amount Registered (2) Proposed Maximum Offering Price Per Share Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee (2) (3) Equity Ordinary Shares, $0.

PEAK BIO Consolidated Financial Statements As of and for the Years Ended December 31, 2023 and 2022

Exhibit 99.1 PEAK BIO Consolidated Financial Statements As of and for the Years Ended December 31, 2023 and 2022 Page Report of Independent Registered Public Accounting Firm (PCAOB ID: 688) F-2 Consolidated Balance Sheets F-3 Consolidated Statements of Operations and Comprehensive Loss F-4 Consolidated Statements of Equity (Deficit) F-5 Consolidated Statements of Cash Flows F-6 Notes to Consolidat

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 25, 2024 Akari Therapeutics, Plc (Exact Name of Registrant as Specified in Charter) England and Wales 001-36288 98-1034922 (State or other jurisdiction of incorporation) (Comm

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-36288 Akari Thera

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 19, 2024 Akari Therapeutics, Plc (Exact Name of Registrant as Specified in Charter) England and Wales 001-36288 98-1034922 (State or other jurisdiction of incorporation) (Commi

Side Letter Agreement, dated August 15, 2024, by and among Akari Therapeutics, Plc, Pegasus Merger Sub, Inc. and Peak Bio, Inc.(incorporated by reference to Exhibit 10.5 to Registrant’s Quarterly Report on Form 10-Q, as filed with the SEC on August 19, 2024).

Exhibit 10.5 August 15, 2024 Side Letter Agreement Akari Therapeutics, Plc 22 Boston Wharf Road FL 7 Boston, MA 02210 Attention: Samir R. Patel, M.D. Pegasus Merger Sub, Inc. 22 Boston Wharf Road FL 7 Boston, MA 02210 Attention: Samir R. Patel, M.D. Peak Bio, Inc. 4900 Hopyard Road, Suite100 Pleasanton, CA 94588 Attention: Hoyoung Huh Re : Extension of Merger Agreement Termination Date Ladies and

Form of Convertible Promissory Note, dated May 10, 2024, by and between Akari Therapeutics, Plc and the purchasers party thereto.

Exhibit 10.3 THIS NOTE AND THE SECURITIES ISSUABLE UPON THE CONVERSION HEREOF HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED. THEY MAY NOT BE SOLD, OFFERED FOR SALE, PLEDGED, HYPOTHECATED, OR OTHERWISE TRANSFERRED EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR AN OPINION OF COUNSEL SATISFACTORY TO MAKER THAT REGISTRATI

Akari Therapeutics Reports Second Quarter 2024 Financial Results and Recent Highlights Samir R. Patel, M.D. Appointed Interim CEO; Interim CEO Employment Contract Demonstrates Alignment with Shareholders Plan for Prioritization of Peak Bio’s ADC Canc

Exhibit 99.1 Akari Therapeutics Reports Second Quarter 2024 Financial Results and Recent Highlights Samir R. Patel, M.D. Appointed Interim CEO; Interim CEO Employment Contract Demonstrates Alignment with Shareholders Plan for Prioritization of Peak Bio’s ADC Cancer Therapeutic Platform Technology and Akari’s PAS-nomacopan for Geographic Atrophy Existing Investors Support the Company with Issuance

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING SEC FILE NUMBER 001-39290 CUSIP NUMBER 97382D 501 (Check One): ☐ Form 10-K ☐ Form 20-F ☐ Form 11-K ☒ Form 10-Q ☐ Form 10-D ☐ Form N-CEN ☐ Form N-CSR For Period Ended: June 30, 2024 ☐ Transition Report on Form 10-K ☐ Transition Report on Form 20-F ☐ Transition Report on Form 11-K ☐ Transi

Submission of Matters to a Vote of Security Holders

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 28, 2024 Akari Therapeutics, Plc (Exact Name of Registrant as Specified in Charter) England and Wales 001-36288 98-1034922 (State or other jurisdiction of incorporation) (Commiss

AKTX / Akari Therapeutics, Plc - Depositary Receipt (Common Stock) / RPC Pharma Ltd - SC 13D/A Activist Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A Under the Securities Exchange Act of 1934 (Amendment No. 8)* Akari Therapeutics, Plc (Name of Issuer) Ordinary Shares, $0.0001 par value (Title of Class of Securities) 00972G207 (CUSIP Number) Jennifer L. Porter, Esquire Justin S. Platt, Esquire Goodwin Procter LLP 620 8th Ave New York, NY 10018 +1 212 813 8800

AKTX / Akari Therapeutics, Plc - Depositary Receipt (Common Stock) / Theofilos Charles Steve Activist Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. )* Akari Therapeutics Plc (Name of Issuer) Ordinary Shares, par value $0.0001 per share (Title of Class of Securities) 00972G207 (CUSIP Number) Jay H. Knight Barnes & Thornburg LLP 1600 West End Avenue, Suite 800 Nashville, Tennessee 37203-3494 (615) 621-610

AKTX / Akari Therapeutics, Plc - Depositary Receipt (Common Stock) / Patel Samir Rashmikant - SCHEDULE 13D Activist Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION, Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 Akari Therapeutics, PLC (Name of Issuer) Ordinary Shares, par value $0.0001 per share (represented by American Depositary Shares) (Title of Class of Securities) 00972G207 (CUSIP Number) Rob Condon Dentons US LLP 1221 Avenue of the Americas New York, NY 10020 (212) 768-670

Interim Chief Executive Officer Agreement, dated as of May 31, 2024, by and between the Company and Samir Patel, M.D.

Exhibit 10.1 INTERIM CHIEF EXECUTIVE OFFICER AGREEMENT Effective May 1, 2024, (the “Start Date”), Samir R. Patel, M.D. (“Interim CEO”) and Akari Therapeutics, Plc (the “Company”) agree as follows:a 1. Services; Payment; No Violation of Rights or Obligations. Interim CEO agrees to undertake and complete the Services (as defined in Exhibit A) in accordance with and on the schedule specified in Exhib

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 31, 2024 Akari Therapeutics, Plc (Exact Name of Registrant as Specified in Charter) England and Wales 001-36288 98-1034922 (State or other jurisdiction of incorporation) (Commissi

Form of Placement Agent Warrant (incorporated by reference to Exhibit 4.2 to Registrant’s Current Report on Form 8-K, as filed with the SEC on June 4, 2024).

Exhibit 4.2 NEITHER THIS SECURITY NOR THE SECURITIES INTO WHICH THIS SECURITY IS EXERCISABLE HAS BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR

SECURITIES PURCHASE AGREEMENT

Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of May 29, 2024 between Akari Therapeutics, Plc, a public company with limited liability incorporated under the laws of England and Wales (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively

Form of Series C Warrant (incorporated by reference to Exhibit 4.1 to Registrant’s Current Report on Form 8-K, as filed with the SEC on June 4, 2024).

Exhibit 4.1 NEITHER THIS SECURITY NOR THE SECURITIES INTO WHICH THIS SECURITY IS EXERCISABLE HAS BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR

Form of Securities Purchase Agreement, dated May 29, 2024, by and among Akari Therapeutics, Plc and the purchasers party thereto (incorporated by reference to Exhibit 10.1 to Registrant’s Current Report on Form 8-K, as filed with the SEC on June 4, 2024).

Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of May 29, 2024 between Akari Therapeutics, Plc, a public company with limited liability incorporated under the laws of England and Wales (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively

NOTICE OF EXERCISE

Exhibit 4.1 NEITHER THIS SECURITY NOR THE SECURITIES INTO WHICH THIS SECURITY IS EXERCISABLE HAS BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR

PLACEMENT AGENT WARRANT TO PURCHASE ORDINARY SHARES REPRESENTED BY AMERICAN DEPOSITARY SHARES AKARI THERAPEUTICS, PLC.

Exhibit 4.2 NEITHER THIS SECURITY NOR THE SECURITIES INTO WHICH THIS SECURITY IS EXERCISABLE HAS BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 29, 2024 Akari Therapeutics,

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 29, 2024 Akari Therapeutics, Plc (Exact Name of Registrant as Specified in Charter) England and Wales 001-36288 98-1034922 (State or other jurisdiction of incorporation) (Commissi

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 29, 2024 Akari Therapeutics,

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 29, 2024 Akari Therapeutics, Plc (Exact Name of Registrant as Specified in Charter) England and Wales 001-36288 98-1034922 (State or other jurisdiction of incorporation) (Commissi

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(A) OF THE SECURITIES EXCHANGE ACT OF 1934 (AMENDMENT NO.        )

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(A) OF THE SECURITIES EXCHANGE ACT OF 1934 (AMENDMENT NO.        ) Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))

Akari Therapeutics Reports First Quarter 2024 Financial Results and Recent Highlights Entered into a Definitive Merger Agreement with Peak Bio; Expected to Close in the Third Quarter of 2024 Samir R. Patel, M.D. Appointed Interim CEO Plan for Priorit

Exhibit 99.1 Akari Therapeutics Reports First Quarter 2024 Financial Results and Recent Highlights Entered into a Definitive Merger Agreement with Peak Bio; Expected to Close in the Third Quarter of 2024 Samir R. Patel, M.D. Appointed Interim CEO Plan for Prioritization of Peak Bio’s ADC Cancer Therapeutic Platform Technology and Akari’s PAS-nomacopan for Geographic Atrophy Implementation of Restr

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 16, 2024 Akari Therapeutics, Plc (Exact Name of Registrant as Specified in Charter) England and Wales 001-36288 98-1034922 (State or other jurisdiction of incorporation) (Commissi

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-36288 Akari Ther

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Costs Associated with Exit or Disposal Activities

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 1, 2024 Akari Therapeutics, Plc (Exact Name of Registrant as Specified in Charter) England and Wales 001-36288 98-1034922 (State or other jurisdiction of incorporation) (Commissio

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 25, 2024 Akari Therapeutics

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 25, 2024 Akari Therapeutics, Plc (Exact Name of Registrant as Specified in Charter) England and Wales 001-36288 98-1034922 (State or other jurisdiction of incorporation) (Commis

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 25, 2024 Akari Therapeutics, Plc (Exact Name of Registrant as Specified in Charter) England and Wales 001-36288 98-1034922 (State or other jurisdiction of incorporation) (Commis

Akari Therapeutics and Peak Bio Announce Portfolio Prioritization Plan for Combined Go-Forward Merger Entity

Exhibit 99.1 Akari Therapeutics and Peak Bio Announce Portfolio Prioritization Plan for Combined Go-Forward Merger Entity • Prioritization of Peak’s ADC cancer therapeutic platform technology and Akari’s PAS-nomacopan for Geographic Atrophy, a disabling ophthalmic disease • Akari Therapeutics announces leadership changes in separate Akari press release BOSTON and PLEASANTON, May 1, 2024 (GLOBE NEW

Akari Therapeutics and Peak Bio Announce Portfolio Prioritization Plan for Combined Go-Forward Merger Entity

Exhibit 99.1 Akari Therapeutics and Peak Bio Announce Portfolio Prioritization Plan for Combined Go-Forward Merger Entity • Prioritization of Peak’s ADC cancer therapeutic platform technology and Akari’s PAS-nomacopan for Geographic Atrophy, a disabling ophthalmic disease • Akari Therapeutics announces leadership changes in separate Akari press release BOSTON and PLEASANTON, May 1, 2024 (GLOBE NEW

AMENDMENT NO. 2 TO CONSULTING SERVICES AGREEMENT

Exhibit 10.1 AMENDMENT NO. 2 TO CONSULTING SERVICES AGREEMENT This Amendment No. 2 (“Amendment”) is entered into as of April 26, 2024 (“Effective Date”) by and between Board Advantage LLC, with an address of (“Consultant”), and Akari Therapeutics, Inc. located at 22 Boston Wharf Road, Fl 7, Boston, MA 02210 (“Akari”), and amends the Consulting Agreement dated July 17, 2023 and Amendment #1 dated S

Amendment No. 2 to Consulting Services Agreement, by and between the Company and Board Advantage LLC, dated April 26, 2024

Exhibit 10.1 AMENDMENT NO. 2 TO CONSULTING SERVICES AGREEMENT This Amendment No. 2 (“Amendment”) is entered into as of April 26, 2024 (“Effective Date”) by and between Board Advantage LLC, with an address of (“Consultant”), and Akari Therapeutics, Inc. located at 22 Boston Wharf Road, Fl 7, Boston, MA 02210 (“Akari”), and amends the Consulting Agreement dated July 17, 2023 and Amendment #1 dated S

Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 5, 2024 Akari Therapeutics, Plc (Exact Name of Registrant as Specified in Charter) England and Wales 001-36288 98-1034922 (State or other jurisdiction of incorporation) (Commiss

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 1, 2024 Akari Therapeutics,

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 1, 2024 Akari Therapeutics, Plc (Exact Name of Registrant as Specified in Charter) England and Wales 001-36288 98-1034922 (State or other jurisdiction of incorporation) (Commiss

Akari Therapeutics Reports Full-Year 2023 Financial Results and Recent Highlights

Exhibit 99.1 Akari Therapeutics Reports Full-Year 2023 Financial Results and Recent Highlights BOSTON and LONDON, April 1, 2024 (GLOBE NEWSWIRE) – Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biotechnology company developing advanced therapies for autoimmune and inflammatory diseases, has reported financial results for the full year 2023 as well as recent company highlights. “Amidst challe

Description of the Akari Therapeutics Plc Securities Registered Under Section 12 of the Securities Exchange Act of 1934. (incorporated by reference to Exhibit 4.7 to the Registrant’s Annual Report on Form 10-K filed with the SEC on March 29, 2024)

Exhibit 4.7 DESCRIPTION OF SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED The following description is a summary of the material terms of Akari Therapeutics, Plc (the “Company”) ordinary shares with a par value $0.0001 per share and American Depositary Shares (the “ADSs”), each representing 2,000 ordinary shares. This description also summarizes rel

Stock Option Agreement between the Registrant and Wendy F. DiCicco dated July 17, 2023. (incorporated by reference to Exhibit 10.29 to the Registrant’s Annual Report on Form 10-K filed with the SEC on March 29, 2024)

Exhibit 10.29 STOCK OPTION AGREEMENT United States Participants (NSO) AGREEMENT made as of the date of the grant set forth in Exhibit A (the “Effective Date”) by and between Akari Therapeutics, Plc, a company formed under the laws of England and Wales, and having a place of business at 22 Boston Wharf Road, Floor 7, Boston, MA 02210, USA (the “Company”) and the individual whose name and address ap

Restricted Stock Unit Agreement between the Company and Rachelle Jacques dated June 1, 2023.

Exhibit 10.25 AKARI THERAPEUTICS, PLC 2023 EQUITY INCENTIVE PLAN RESTRICTED STOCK UNIT AGREEMENT PARTICIPANT: Rachelle Jacques NUMBER OF RSUs: 218,055,800 DATE OF GRANT: June 30, 2023 Akari Therapeutics, Plc, a public limited company formed under the laws of England and Wales (the “Company”), is pleased to confirm that the Participant has been granted a Restricted Stock Unit Award (this “Award”),

Form of ISO/NQ Stock Option Agreement Granted Under the 2023 Equity Incentive Plan (incorporated by reference to Exhibit 10.6 to the Registrant’s Annual Report on Form 10-K filed with the SEC on March 29, 2024)

Exhibit 10.6 STOCK OPTION AGREEMENT United States Participants (ISO/NSO) AGREEMENT made as of the date of the grant set forth in Exhibit A (the “Effective Date”) by and between Akari Therapeutics, Plc, a company formed under the laws of England and Wales, and having a place of business at 22 Boston Wharf Road, Floor 7, Boston, MA 02210, USA (the “Company”) and the individual whose name and address

Stock Option Agreement between the Company and Rachelle Jacques dated March 28, 2023.

Exhibit 10.24 AKARI THERAPEUTICS, PLC 2014 EQUITY INCENTIVE PLAN RESTRICTED STOCK UNIT AGREEMENT PARTICIPANT: Rachelle Jacques NUMBER OF RSUs: 189,787,200 DATE OF GRANT: March 28, 2023 Akari Therapeutics, Plc, a public limited company formed under the laws of England and Wales (the “Company”), is pleased to confirm that the Participant has been granted a Restricted Stock Unit Award (this “Award”),

List of Subsidiaries. (incorporated by reference to Exhibit 21.1 to the Registrant’s Annual Report on Form 10-K filed with the SEC on March 29, 2024)

Exhibit 21.1 Subsidiaries of Akari Therapeutics, Plc The following table sets forth the name and jurisdiction of incorporation of our subsidiaries: Name of Subsidiary Jurisdiction of Incorporation Celsus Therapeutics Inc. Delaware Morria Biopharma Ltd. Israel Volution Immuno Pharmaceuticals SA Switzerland Akari Malta Limited Malta

Form of Restricted Stock Unit Agreement Granted Under the 2023 Equity Incentive Plan (incorporated by reference to Exhibit 10.7 to the Registrant’s Annual Report on Form 10-K filed with the SEC on March 29, 2024)

Exhibit 10.7 AKARI THERAPEUTICS, PLC 2023 EQUITY INCENTIVE PLAN RESTRICTED STOCK UNIT AGREEMENT PARTICIPANT: NUMBER OF RSUs: DATE OF GRANT: Akari Therapeutics, Plc, a public limited company formed under the laws of England and Wales (the “Company”), is pleased to confirm that the Participant has been granted a Restricted Stock Unit Award (this “Award”), effective as of the Date of Grant set forth

Clawback Policy.

Exhibit 97 Akari Therapeutics, Plc Executive Officer Clawback Policy Approved by the Board of Directors on November 27, 2023 (the “Adoption Date”) I.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-36288 Akari Therapeut

Amendment No. 1 to Consulting Agreement between the Company and Wendy DiCicco dated September 1, 2023.

Exhibit 10.27 AMENDMENT NO. 1 TO CONSULTING SERVICES AGREEMENT This Amendment No. 1 (“Amendment”) is entered into as of September 1, 2023 ("Effective Date") by and between Board Advantage LLC, with an address of 948 Drovers Lane, Chester Springs, PA 19425 ("Consultant"), and Akari Therapeutics, Inc. located at 22 Boston Wharf Road, Fl 7, Boston, MA 02210 ("Akari"), and amends the Consulting Agreem

Consulting Agreement between the Company and Wendy DiCicco dated July 17, 2023.

Exhibit 10.26 CONSULTING SERVICES AGREEMENT This Consulting Services Agreement ("Agreement") isentered into as of July 17, 2023 ("Effective Date") by and between Board Advantage LLC, with an address of 948 Drovers Lane, Chester Springs, PA 19425 ("Consultant"), and Akari Therapeutics, Inc. located at 1460 Broadway, New York, NY 10036 ("Akari"). Consultant and Akari are each referredto individually

Consulting Agreement between the Company and Wendy F. DiCicco dated January 15, 2024.

Exhibit 10.28 CONSULTING SERVICES AGREEMENT This Consulting Services Agreement ("Agreement") is entered into as of January 15, 2024 ("Effective Date") by and between Board Advantage LLC, with an address of 948 Drovers Lane, Chester Springs, PA 19425 ("Consultant"), and Akari Therapeutics, Inc. located at 22 Boston Wharf Road FL 7, Boston, MA 02210 ("Akari"). Consultant and Akari are each referred

Form of Securities Purchase Agreement dated as of March 11, 2024 between Akari Therapeutics, Plc and the purchasers party thereto (incorporated by reference to Exhibit 10.1 previously filed with the Registrant’s Current Report on Form 8-K as filed with the SEC on March 11, 2024).

Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of March 11, 2024 between Akari Therapeutics, Plc, a public company with limited liability incorporated under the laws of England and Wales (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectivel

Form of Securities Purchase Agreement, dated March 11, 2024, by and among Akari Therapeutics, Plc and the purchasers party thereto

Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of March 11, 2024 between Akari Therapeutics, Plc, a public company with limited liability incorporated under the laws of England and Wales (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectivel

Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): March 11, 2024 AKARI THERAPEUTICS, PLC (Exact Name of Registrant as Specified in Charter) England and Wales 001-36288 NA (State or other jurisdiction of incorporation) (Commission Fil

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): March 11, 2024 AKARI THERAPEUTICS

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): March 11, 2024 AKARI THERAPEUTICS, PLC (Exact Name of Registrant as Specified in Charter) England and Wales 001-36288 NA (State or other jurisdiction of incorporation) (Commission Fil

Akari Therapeutics and Peak Bio Announce Definitive Agreement to Merge as Equals Creating an Expanded Pipeline That Features a Novel Antibody Drug Conjugate (ADC) Toolkit

Exhibit 99.1 Akari Therapeutics and Peak Bio Announce Definitive Agreement to Merge as Equals Creating an Expanded Pipeline That Features a Novel Antibody Drug Conjugate (ADC) Toolkit BOSTON, MA and PLEASANTON, CA – March 5, 2024 (GLOBE NEWSWIRE) — Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biotechnology company developing advanced therapies for autoimmune and inflammatory diseases, and

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 4, 2024 AKARI THERAPEUTICS,

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 4, 2024 AKARI THERAPEUTICS, PLC (Exact Name of Registrant as Specified in Its Charter) England and Wales 001-36288 98-1034922 (State or Other Jurisdiction of Incorporation) (Com

Akari Therapeutics Company Presentation March 2024

Exhibit 99.4 Akari Therapeutics Company Presentation March 2024 2 This communication relates to the proposed transaction pursuant to the terms of the Agreement and Plan of Merger (the “Merger Ag reement”), by and among Akari Therapeutics, Plc, a public company limited by shares incorporated in England and Wales (“ Akari ”),, Pegasus Merger Sub, Inc., a Delaware corporation and a wholly - owned sub

Akari employee communication from Rachelle Jacques:

Exhibit 99.2 Akari employee communication from Rachelle Jacques: Team, Today we issued a press release announcing that Akari and Peak Bio have reached a definitive agreement for a merger of equals in an all-stock transaction. Please see the press release here. This merger is an important step forward for our company. I’d like to discuss this with you and answer your questions personally, so we’ll

Akari investor email (those who have inquired in the past) from Rachelle Jacques:

Exhibit 99.3 Akari investor email (those who have inquired in the past) from Rachelle Jacques: [Name], I wanted to reach out personally and share the news we issued this morning. Akari and Peak Bio have reached a definitive agreement for a merger of equals in an all-stock transaction. Please see the press release here. What is most exciting about this merged company, which will operate as Akari an

Regulation FD Disclosure, Entry into a Material Definitive Agreement, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 4, 2024 AKARI THERAPEUTICS, PLC (Exact Name of Registrant as Specified in Its Charter) England and Wales 001-36288 98-1034922 (State or Other Jurisdiction of Incorporation) (Com

Agreement and Plan of Merger, dated as of March 4, 2024, by and among Akari Therapeutics, Plc, Peak Bio, Inc. and Pegasus Merger Sub, Inc.

Exhibit 2.1 Execution Version AGREEMENT AND PLAN OF MERGER BY AND AmONG AKARI THERAPEUTICS, PLC, PEGASUS MERGER SUB, INC. AND PEAK BIO, INC. Dated as of March 4, 2024 Table of Contents Section 1 THE MERGER 2 1.1 The Merger 2 1.2 Effective Time 2 1.3 Closing 2 1.4 Directors and Officers of the Surviving Corporation 3 1.5 Subsequent Actions 3 1.6 Post-Merger Operations 3 Section 2 CONVERSION OF SECU

Form of Voting and Support Agreement, dated as of March 4, 2024, by and among Peak Bio and certain shareholders of Akari (incorporated by reference to Exhibit 10.2 to Registrant's Current Report on Form 8-K, as filed with the SEC on March 5, 2024).

Exhibit 10.2 VOTING AND SUPPORT AGREEMENT This Voting and Support Agreement (this “Agreement”) is made and entered into as of [●], 2024 (the “Agreement Date”), by and among Peak Bio, Inc. (the “Company”), a Delaware corporation and [SHAREHOLDER] (the “Shareholder”). Each of the Company and the Shareholder are sometimes referred to as a “Party” and collectively as the “Parties”. Capitalized terms u

Akari employee communication from Rachelle Jacques:

Exhibit 99.2 Akari employee communication from Rachelle Jacques: Team, Today we issued a press release announcing that Akari and Peak Bio have reached a definitive agreement for a merger of equals in an all-stock transaction. Please see the press release here. This merger is an important step forward for our company. I’d like to discuss this with you and answer your questions personally, so we’ll

Form of Voting and Support Agreement, dated as of March 4, 2024, by and among Akari, and certain stockholders of Peak Bio (incorporated by reference to Exhibit 10.1 to Registrant's Current Report on Form 8-K, as filed with the SEC on March 5, 2024).

Exhibit 10.1 VOTING AND SUPPORT AGREEMENT This Voting and Support Agreement (this “Agreement”) is made and entered into as of [●], 2024 (the “Agreement Date”), by and among Akari Therapeutics, Plc, a public company limited by shares incorporated in England and Wales (“Parent”), and [Stockholder] (the “Stockholder”). Each of Parent and the Stockholder are sometimes referred to as a “Party” and coll

Akari investor email (those who have inquired in the past) from Rachelle Jacques:

Exhibit 99.3 Akari investor email (those who have inquired in the past) from Rachelle Jacques: [Name], I wanted to reach out personally and share the news we issued this morning. Akari and Peak Bio have reached a definitive agreement for a merger of equals in an all-stock transaction. Please see the press release here. What is most exciting about this merged company, which will operate as Akari an

Form of Voting and Support Agreement, dated as of March 4, 2024, by and among Peak Bio and certain shareholders of Akari.

Exhibit 10.2 VOTING AND SUPPORT AGREEMENT This Voting and Support Agreement (this “Agreement”) is made and entered into as of [●], 2024 (the “Agreement Date”), by and among Peak Bio, Inc. (the “Company”), a Delaware corporation and [SHAREHOLDER] (the “Shareholder”). Each of the Company and the Shareholder are sometimes referred to as a “Party” and collectively as the “Parties”. Capitalized terms u

Agreement and Plan of Merger, dated as of March 4, 2024, by and among Akari Therapeutics, Plc, Peak Bio, Inc. and Pegasus Merger Sub, Inc. (incorporated by reference to Exhibit 2.1 to Registrant's Current Report on Form 8-K, as filed with the SEC on March 5, 2024).

Exhibit 2.1 Execution Version AGREEMENT AND PLAN OF MERGER BY AND AmONG AKARI THERAPEUTICS, PLC, PEGASUS MERGER SUB, INC. AND PEAK BIO, INC. Dated as of March 4, 2024 Table of Contents Section 1 THE MERGER 2 1.1 The Merger 2 1.2 Effective Time 2 1.3 Closing 2 1.4 Directors and Officers of the Surviving Corporation 3 1.5 Subsequent Actions 3 1.6 Post-Merger Operations 3 Section 2 CONVERSION OF SECU

Form of Voting and Support Agreement, dated as of March 4, 2024, by and among Akari, and certain stockholders of Peak Bio.

Exhibit 10.1 VOTING AND SUPPORT AGREEMENT This Voting and Support Agreement (this “Agreement”) is made and entered into as of [●], 2024 (the “Agreement Date”), by and among Akari Therapeutics, Plc, a public company limited by shares incorporated in England and Wales (“Parent”), and [Stockholder] (the “Stockholder”). Each of Parent and the Stockholder are sometimes referred to as a “Party” and coll

Akari Therapeutics and Peak Bio Announce Definitive Agreement to Merge as Equals Creating an Expanded Pipeline That Features a Novel Antibody Drug Conjugate (ADC) Toolkit

Exhibit 99.1 Akari Therapeutics and Peak Bio Announce Definitive Agreement to Merge as Equals Creating an Expanded Pipeline That Features a Novel Antibody Drug Conjugate (ADC) Toolkit BOSTON, MA and PLEASANTON, CA – March 5, 2024 (GLOBE NEWSWIRE) — Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biotechnology company developing advanced therapies for autoimmune and inflammatory diseases, and

Filed by Akari Therapeutics, Plc

Filed by Akari Therapeutics, Plc pursuant to Rule 425 under the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12 under the Securities Exchange Act of 1934 Subject Company: Peak Bio, Inc.

Akari Therapeutics Company Presentation March 2024

Exhibit 99.4 Akari Therapeutics Company Presentation March 2024 2 This communication relates to the proposed transaction pursuant to the terms of the Agreement and Plan of Merger (the “Merger Ag reement”), by and among Akari Therapeutics, Plc, a public company limited by shares incorporated in England and Wales (“ Akari ”),, Pegasus Merger Sub, Inc., a Delaware corporation and a wholly - owned sub

US00972G2075 / AKARI THERAPEUTICS PLC SPON ADR / RPC Pharma Ltd - SC 13D/A Activist Investment

SC 13D/A 1 tm241868d1sc13da.htm SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A Under the Securities Exchange Act of 1934 (Amendment No. 7)* Akari Therapeutics, Plc (Name of Issuer) Ordinary Shares, $0.0001 par value (Title of Class of Securities) 00972G207 (CUSIP Number) Gary Emmanuel, Esquire Win Rutherfurd, Esquire Greenberg Traurig, LLP One Vande

Akari Therapeutics Announces Existing Investors Support the Company Through a $2 Million Private Placement Financing

Exhibit 99.1 Akari Therapeutics Announces Existing Investors Support the Company Through a $2 Million Private Placement Financing BOSTON and LONDON, January 2, 2024 (GLOBE NEWSWIRE) - Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biotechnology company developing advanced therapies for autoimmune and inflammatory diseases, today announced that it closed a private placement financing with exi

Regulation FD Disclosure, Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 27, 2023 AKARI THERAPEUTICS, PLC (Exact Name of Registrant as Specified in Charter) England and Wales 001-36288 98-1034922 (State or other jurisdiction of incorporation) (Com

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of: December 2023 Commission file number: 001-

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of: December 2023 Commission file number: 001-36288 Akari Therapeutics, Plc (Translation of registrant’s name into English) 22 Boston Wharf Road FL 7 Boston, MA 02210 (Address of principal executi

Akari Therapeutics Appoints Experienced Life Sciences Entrepreneur Samir R. Patel, M.D. to Board of Directors

Exhibit 99.1 Akari Therapeutics Appoints Experienced Life Sciences Entrepreneur Samir R. Patel, M.D. to Board of Directors NEW YORK and BOSTON, December 1, 2023 (GLOBE NEWSWIRE) — Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biotechnology company developing advanced therapies for autoimmune and inflammatory diseases, today announced the appointment of experienced life sciences entrepreneur

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of: November 2023 Commission file number: 001-

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of: November 2023 Commission file number: 001-36288 Akari Therapeutics, Plc (Translation of registrant’s name into English) 75/76 Wimpole Street London W1G 9RT United Kingdom (Address of principal

Akari Therapeutics Presents Poster on Progress in Pre-Clinical Development of Long-Acting PAS-Nomacopan as a Potential Treatment for Geographic Atrophy at the 4th Annual Dry AMD Therapeutic Development Conference

Exhibit 99.1 Akari Therapeutics Presents Poster on Progress in Pre-Clinical Development of Long-Acting PAS-Nomacopan as a Potential Treatment for Geographic Atrophy at the 4th Annual Dry AMD Therapeutic Development Conference • Positive pre-clinical results, including an advanced high yielding manufacturing process, support the anticipated submission of an IND in 2024 to begin clinical development

AKARI THERAPEUTICS, PLC 1,285,506,000 Ordinary Shares Represented by 642,753 American Depostiary Shares

PROSPECTUS Filed pursuant to Rule 424(b)(3) Registration No. 333-275119 AKARI THERAPEUTICS, PLC 1,285,506,000 Ordinary Shares Represented by 642,753 American Depostiary Shares This prospectus relates to the resale, by the selling shareholders identified in this prospectus, of up to an aggregate of 642,753 American Depositary Shares, or ADSs, representing up to an aggregate of 1,285,506,000 ordinar

Akari Therapeutics, Plc 22 Boston Wharf Road FL 7 Boston, MA 02210

Akari Therapeutics, Plc 22 Boston Wharf Road FL 7 Boston, MA 02210 October 25, 2023 Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.

As filed with the Securities and Exchange Commission on October 20, 2023

As filed with the Securities and Exchange Commission on October 20, 2023 Registration No.

As filed with the Securities and Exchange Commission on October 20, 2023

As filed with the Securities and Exchange Commission on October 20, 2023 Registration No.

As filed with the Securities and Exchange Commission on October 20, 2023

As filed with the Securities and Exchange Commission on October 20, 2023 Registration No.

Filing Fee Table

EX-FILING FEES Calculation of Filing Fee Tables Form F-3 (Form Type) Akari Therapeutics, Plc (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title(1) Fee Calculation Rule Amount Registered(2) Proposed Maximum Offering Price Per Unit(3) Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Ordinary Shares, par value $0.

AKTX / Akari Therapeutics Plc - ADR / RPC Pharma Ltd - SC 13D/A Activist Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A Under the Securities Exchange Act of 1934 (Amendment No. 6)* Akari Therapeutics, Plc (Name of Issuer) Ordinary Shares, $0.0001 par value (Title of Class of Securities) 00972G108 (CUSIP Number) Gary Emmanuel, Esquire Win Rutherfurd, Esquire Greenberg Traurig, LLP One Vanderbilt Avenue New York, NY 10017 +1 212 80

As filed with the Securities and Exchange Commission on October 12, 2023.

As filed with the Securities and Exchange Commission on October 12, 2023. Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Form S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 AKARI THERAPEUTICS, PLC (Exact Name of Registrant as Specified in its Charter) England and Wales 98-1034922 (State or other jurisdiction of incorporation or organizati

Filing Fee Table

EX-FILING FEES Calculation of Filing Fee Tables Form S-8 (Form Type) Akari Therapeutics, Plc (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title(1) Fee Calculation Rule Amount Registered(2) Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Ordinary Shares, par value $0.

2023 Equity Incentive Plan (incorporated by reference to Exhibit 4.8 to the Registrant’s Form S-8, as filed with the SEC on October 12, 2023).

Exhibit 4.8   Akari Therapeutics, Plc   2023 EQUITY INCENTIVE PLAN   1. DEFINITIONS.   Unless otherwise specified or unless the context otherwise requires, the following terms, as used in this Akari Therapeutics, Plc 2023 Equity Incentive Plan, have the following meanings:   Administrator means the committee to which the Board of Directors has delegated the authority to grant equity under the Plan

AKARI THERAPEUTICS, PLC For The Six Month Period Ended June 30, 2023 TABLE OF CONTENTS

Table of Contents Exhibit 99.1 AKARI THERAPEUTICS, PLC For The Six Month Period Ended June 30, 2023 TABLE OF CONTENTS Condensed Consolidated Financial Statements (Unaudited) Page Condensed Consolidated Balance Sheets as of June 30, 2023 and December 31, 2022 2 Condensed Consolidated Statements of Operations and Comprehensive Loss for the Six Months Ended June 30, 2023 and 2022 3 Condensed Consolid

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of: September 2023 Commission file number: 001

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of: September 2023 Commission file number: 001-36288 AKARI THERAPEUTICS, PLC (Translation of registrant’s name into English) 22 Boston Wharf Road FL 7 Boston, MA 02210 (Address of principal execut

Akari Therapeutics Reports First Half 2023 Financial Results and Highlights

Exhibit 99.3 Akari Therapeutics Reports First Half 2023 Financial Results and Highlights · Akari’s priority pipeline programs remain on track to begin enrollment in the registrational nomacopan Phase 3 clinical trials in pediatric and adult HSCT-TMA and start PAS-nomacopan clinical trials in geographic atrophy (GA) · Granted orphan drug designation from the European Commission for treatment in hem

Management’s Discussion and Analysis of Financial Condition and Results of Operations

Exhibit 99.2 Management’s Discussion and Analysis of Financial Condition and Results of Operations The following discussion and analysis of our financial condition and results of operations should be read together with: ● our unaudited condensed consolidated financial statements, related notes and other financial information included elsewhere in this Current Report on Form 6-K; and ● our audited

Form of Pre-Funded Warrant (incorporated by reference to the exhibit previously filed with the Registrant’s Report on Form 6-K filed on September 21, 2023)

Exhibit 10.2 NEITHER THIS SECURITY NOR THE SECURITIES INTO WHICH THIS SECURITY IS EXERCISABLE HAS BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGIST

Form of Placement Agent Warrant issued under the Securities Purchase Agreement dated as of September 20, 2023 between Akari Therapeutics, Plc and the investors listed therein (incorporated by reference to Exhibit 10.3 to Registrant’s Current Report on Form 8-K, as filed with the SEC on September 21, 2023.

Exhibit 10.3 THE SECURITIES REPRESENTED HEREBY HAVE NOT BEEN REGISTERED UNDER THE U.S. SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”) AND ARE “RESTRICTED SECURITIES” AS DEFINED IN RULE 144 PROMULGATED UNDER THE ACT. THE SECURITIES MAY NOT BE OFFERED, SOLD, PLEDGED, OR OTHERWISE DISTRIBUTED OR TRANSFERRED EXCEPT (i) PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE ACT OR (ii) PURSUANT TO A

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of: September 2023 Commission file number: 001

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of: September 2023 Commission file number: 001-36288 Akari Therapeutics, Plc (Translation of registrant’s name into English) 75/76 Wimpole Street London W1G 9RT United Kingdom (Address of principa

Akari Therapeutics Announces Existing Investors Support the Company Through a $2 Million Private Placement Financing, Company Also Receives $2.5 Million U.K. R&D Tax Credit

Exhibit 99.1 Akari Therapeutics Announces Existing Investors Support the Company Through a $2 Million Private Placement Financing, Company Also Receives $2.5 Million U.K. R&D Tax Credit BOSTON and LONDON, September 21, 2023 (GLOBE NEWSWIRE) - Akari Therapeutics, Plc (Nasdaq: AKTX) (“Akari” or the “Company”), a late-stage biotechnology company developing advanced therapies for autoimmune and inflam

Form of Securities Purchase Agreement dated as of September 20, 2023 between Akari Therapeutics, Plc and the investors listed therein (incorporated by reference to the exhibit previously filed with the Registrant’s Report on Form 6-K filed on September 21, 2023)

Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of September 20, 2023, between Akari Therapeutics, Plc, a public company with limited liability incorporated under the laws of England and Wales (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collec

Akari Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement

Exhibit 99.1 Akari Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement NEW YORK and LONDON, September 5, 2023 (GLOBE NEWSWIRE) – Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biotechnology company developing advanced therapies for autoimmune and inflammatory diseases today announced the company has received written notification from Nasdaq that it has regained complian

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of: September 2023 Commission file number: 001

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of: September 2023 Commission file number: 001-36288 Akari Therapeutics, Plc (Translation of registrant’s name into English) 75/76 Wimpole Street London W1G 9RT United Kingdom (Address of principa

Akari Therapeutics Announces Establishment of Boston U.S. Headquarters Office to Support Expanding Operations and Start of Registrational Phase 3 Clinical Trials

Exhibit 99.1 Akari Therapeutics Announces Establishment of Boston U.S. Headquarters Office to Support Expanding Operations and Start of Registrational Phase 3 Clinical Trials NEW YORK and LONDON, August 18, 2023 (GLOBE NEWSWIRE) – Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biotechnology company developing advanced therapies for autoimmune and inflammatory diseases today announced the est

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of: August 2023 Commission file number: 001-36

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of: August 2023 Commission file number: 001-36288 Akari Therapeutics, Plc (Translation of registrant’s name into English) 75/76 Wimpole Street London W1G 9RT United Kingdom (Address of principal e

As filed with the United States Securities and Exchange Commission on August 17, 2023

As filed with the United States Securities and Exchange Commission on August 17, 2023 Registration No.

AMENDMENT NO. 3 TO DEPOSIT AGREEMENT

Exhibit (a)(4) AMENDMENT NO. 3 TO DEPOSIT AGREEMENT AMENDMENT No. 3 (the “Amendment”) dated as of August , 2023 to the Deposit Agreement (the “Effective Date”), dated as of December 7, 2012, as previously amended as of December 24, 2013 and September 9, 2015 (as amended from time to time, the "Deposit Agreement"), by and among (i) Akari Therapeutics, Plc, a company incorporated under the laws of E

Certification under Rule 466

Exhibit (e) Certification under Rule 466 The depositary, Deutsche Bank Trust Company Americas, represents and certifies the following: (1) That it previously had filed a registration statement on Form F-6 (Akari Therapeutics, Plc, 333-185197) that the Commission declared effective, with terms of deposit identical to the terms of deposit of this registration statement.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of: August 2023 Commission file number: 001-36

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of: August 2023 Commission file number: 001-36288 Akari Therapeutics, Plc (Translation of registrant’s name into English) 75/76 Wimpole Street London W1G 9RT United Kingdom (Address of principal e

Akari Therapeutics, Plc Announces ADS Ratio Change

Exhibit 99.1 Akari Therapeutics, Plc Announces ADS Ratio Change NEW YORK and LONDON, August 15, 2023 (GLOBE NEWSWIRE) – Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biotechnology company developing advanced therapies for autoimmune and inflammatory diseases, today announced that Akari will change the ratio of its American Depositary Shares (ADSs) to ordinary shares from one ADS representin

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of: August 2023 Commission file number: 001-36

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of: August 2023 Commission file number: 001-36288 AKARI THERAPEUTICS, PLC (Translation of registrant’s name into English) 75/76 Wimpole Street London W1G 9RT United Kingdom (Address of principal e

Akari Therapeutics Announces the Appointment of Beth-Anne Lang as Senior Vice President, Regulatory Affairs

Exhibit 99.1 Akari Therapeutics Announces the Appointment of Beth-Anne Lang as Senior Vice President, Regulatory Affairs NEW YORK and LONDON, August 2, 2023 (GLOBE NEWSWIRE) - Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biotechnology company developing advanced therapeutics for autoimmune and inflammatory diseases, today announced the appointment of Beth-Anne Lang, as Senior Vice Presiden

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of: July 2023 Commission file number: 001-3628

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of: July 2023 Commission file number: 001-36288 Akari Therapeutics, Plc (Translation of registrant’s name into English) 75/76 Wimpole Street London W1G 9RT United Kingdom (Address of principal exe

Akari Therapeutics Granted Nomacopan Orphan Drug Designation from the European Commission for Treatment in Hematopoietic Stem Cell Transplantation

Exhibit 99.1 Akari Therapeutics Granted Nomacopan Orphan Drug Designation from the European Commission for Treatment in Hematopoietic Stem Cell Transplantation NEW YORK and LONDON, July 27, 2023 (GLOBE NEWSWIRE) — Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biotechnology company developing advanced therapies for autoimmune and inflammatory diseases, today announced that the European Commi

Akari Therapeutics July 2023

Exhibit 99.1 Akari Therapeutics July 2023 2 Certain statements in this presentation constitute “forward - looking” statements within the meaning of Section 27A of the Securit ies Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These forward - looking statements reflect the current views of Akari Therapeutics, Plc (the “Company”, “we”,. “our” and “us”) and its p lans, intentions

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of: July 2023 Commission file number: 001-3628

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of: July 2023 Commission file number: 001-36288 Akari Therapeutics, Plc (Translation of registrant’s name into English) 75/76 Wimpole Street London W1G 9RT United Kingdom (Address of principal exe

Akari Therapeutics Appoints Experienced Life Sciences Executive Wendy DiCicco as Interim Chief Financial Officer

Exhibit 99.1 Akari Therapeutics Appoints Experienced Life Sciences Executive Wendy DiCicco as Interim Chief Financial Officer NEW YORK and LONDON, July 19, 2023 (GLOBE NEWSWIRE) — Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biotechnology company developing advanced therapies for autoimmune and inflammatory diseases, today announced the appointment of experienced life sciences executive We

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of: July 2023 Commission file number: 001-3628

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of: July 2023 Commission file number: 001-36288 Akari Therapeutics, Plc (Translation of registrant’s name into English) 75/76 Wimpole Street London W1G 9RT United Kingdom (Address of principal exe

Akari Therapeutics Provides Updates on Development of Nomacopan in Pediatric and Adult HSCT-TMA

Exhibit 99.1 Akari Therapeutics Provides Updates on Development of Nomacopan in Pediatric and Adult HSCT-TMA · Akari is on track for start of enrollment by the end of 2023 in the registrational Phase 3 study of nomacopan in pediatric HSCT-TMA · Akari is moving forward into a Phase 3 double-blind placebo-controlled clinical trial of nomacopan in adult HSCT-TMA and will begin enrollment in 2024 NEW

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of: July 2023 Commission file number: 001-3628

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of: July 2023 Commission file number: 001-36288 Akari Therapeutics, Plc (Translation of registrant’s name into English) 75/76 Wimpole Street London W1G 9RT United Kingdom (Address of principal exe

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of: July 2023 Commission file number: 001-3628

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of: July 2023 Commission file number: 001-36288 Akari Therapeutics, Plc (Translation of registrant’s name into English) 75/76 Wimpole Street London W1G 9RT United Kingdom (Address of principal exe

Akari Therapeutics Provides Update on Development of Long-Acting PAS-Nomacopan for Treatment of Geographic Atrophy

Exhibit 99.1 Akari Therapeutics Provides Update on Development of Long-Acting PAS-Nomacopan for Treatment of Geographic Atrophy · Akari has completed evaluation of long-acting PAS-nomacopan candidates and selected a single drug candidate to move forward into clinical trials for treatment of geographic atrophy (GA) · The company remains on track for an IND submission in the first half of 2024 and t

Amended Articles of Association of Akari Therapeutics, Plc (incorporated by reference to the Exhibit 3.1 to Registrant’s Current Report on Form 6-K, as filed with the SEC on July 7, 2023).

Exhibit 3.1 AKARI THERAPEUTICS, PLC Company No. 05252842 ARTICLES OF ASSOCIATION The Companies Act 2006 Public Company Limited by Shares (Adopted by Special Resolution of the Company passed on 8 December 2020 and amended by Special Resolution of the Company passed on 30 June 2023) CONTENTS 1. Preliminary 1 2. Liability of members 4 3. Share capital and variation of rights 4 4. Certificates and sha

Form 6-K filed with the SEC on July 7, 2023

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of: July 2023 Commission file number: 001-36288 Akari Therapeutics, Plc (Translation of registrant’s name into English) 75/76 Wimpole Street London W1G 9RT United Kingdom (Address of principal exe

Akari Therapeutics Receives Positive Opinion on Orphan Drug Designation from the European Medicines Agency for Nomacopan for Treatment in Hematopoietic Stem Cell Transplantation

Exhibit 99.1 Akari Therapeutics Receives Positive Opinion on Orphan Drug Designation from the European Medicines Agency for Nomacopan for Treatment in Hematopoietic Stem Cell Transplantation NEW YORK and LONDON, July 6, 2023 (GLOBE NEWSWIRE) — Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biotechnology company developing advanced therapies for autoimmune and inflammatory diseases, today ann

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of: July 2023 Commission file number: 001-3628

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of: July 2023 Commission file number: 001-36288 Akari Therapeutics, Plc (Translation of registrant’s name into English) 75/76 Wimpole Street London W1G 9RT United Kingdom (Address of principal exe

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of: July 2023 Commission file number: 001-3628

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of: July 2023 Commission file number: 001-36288 Akari Therapeutics, Plc (Translation of registrant’s name into English) 75/76 Wimpole Street London W1G 9RT United Kingdom (Address of principal exe

Akari Therapeutics Appoints Industry Veteran Wa’el Hashad to Board of Directors

Exhibit 99.1 Akari Therapeutics Appoints Industry Veteran Wa’el Hashad to Board of Directors NEW YORK and LONDON, July 5, 2023 (GLOBE NEWSWIRE) — Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biotechnology company developing advanced therapies for autoimmune and inflammatory diseases, today announced the appointment of industry veteran Wa’el Hashad to the Akari Board of Directors as an inde

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of: June 2023 Commission file number: 001-3628

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of: June 2023 Commission file number: 001-36288 Akari Therapeutics, Plc (Translation of registrant’s name into English) 75/76 Wimpole Street London W1G 9RT United Kingdom (Address of principal exe

AKARI THERAPEUTICS, PLC ANNUAL REPORT AND CONSOLIDATED FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2022 Registered in England and Wales, number: 05252842

Exhibit 99.3 AKARI THERAPEUTICS, PLC ANNUAL REPORT AND CONSOLIDATED FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2022 Registered in England and Wales, number: 05252842 AKARI THERAPEUTICS PLC CONSOLIDATED ANNUAL REPORT AND FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2022 CONTENTS Page Officers and professional advisers 1 Directors’ report 2-5 Strategic Report 6-12 Director’s Remunera

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of: June 2023 Commission file number: 001-3628

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of: June 2023 Commission file number: 001-36288 Akari Therapeutics, Plc (Translation of registrant’s name into English) 75/76 Wimpole Street London W1G 9RT United Kingdom (Address of principal exe

AKARI THERAPEUTICS, PLC PROXY FORM For use at the Annual General Meeting to be held at 75/76 Wimpole Street, London W1G 9RT at 2.00pm local time on June 30, 2023.

Exhibit 99.2 Company number 05252842 AKARI THERAPEUTICS, PLC PROXY FORM For use at the Annual General Meeting to be held at 75/76 Wimpole Street, London W1G 9RT at 2.00pm local time on June 30, 2023. I/We (Name in full block capitals please) of being (a) member(s) of Akari Therapeutics, Plc ("Akari" or the "Company") hereby appoint the Chairman of the meeting or as my/our proxy to attend, speak an

THIS DOCUMENT IS IMPORTANT AND REQUIRES YOUR IMMEDIATE ATTENTION

Exhibit 99.1 THIS DOCUMENT IS IMPORTANT AND REQUIRES YOUR IMMEDIATE ATTENTION If you are in any doubt as to what action you should take, you are recommended to seek your own financial advice from your stockbroker or other independent adviser authorized under the Financial Services and Markets Act 2000 (as amended). If you have recently sold or transferred all of your shares in AKARI THERAPEUTICS,

As filed with the Securities and Exchange Commission on May 31, 2023.

As filed with the Securities and Exchange Commission on May 31, 2023. Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Form S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 AKARI THERAPEUTICS, PLC (Exact Name of Registrant as Specified in its Charter) England and Wales 98-1034922 (State or other jurisdiction of incorporation or organization)

Filing Fee Table

EX-FILING FEES Calculation of Filing Fee Tables Form S-8 (Form Type) Akari Therapeutics, Plc (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title(1) Fee Calculation Rule Amount Registered(2) Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Ordinary Shares, par value $0.

As filed with the Securities and Exchange Commission on May 31, 2023

As filed with the Securities and Exchange Commission on May 31, 2023 Registration No.

As filed with the Securities and Exchange Commission on May 31, 2023

As filed with the Securities and Exchange Commission on May 31, 2023 Registration No.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of: May 2023 Commission file number: 001-36288

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of: May 2023 Commission file number: 001-36288 Akari Therapeutics, Plc (Translation of registrant’s name into English) 75/76 Wimpole Street London W1G 9RT United Kingdom (Address of principal exec

Akari Therapeutics May 2023

Exhibit 99.1 Akari Therapeutics May 2023 2 Certain statements in this presentation constitute “forward - looking” statements within the meaning of Section 27A of the Securit ies Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These forward - looking statements reflect the current views of Akari Therapeutics, Plc (the “Company”, “we”,. “our” and “us”) and its p lans, intentions,

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of: May 2023 Commission file number: 001-36288

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of: May 2023 Commission file number: 001-36288 Akari Therapeutics, Plc (Translation of registrant’s name into English) 75/76 Wimpole Street London W1G 9RT United Kingdom (Address of principal exec

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of: May 2023 Commission file number: 001-36288

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of: May 2023 Commission file number: 001-36288 Akari Therapeutics, Plc (Translation of registrant’s name into English) 75/76 Wimpole Street London W1G 9RT United Kingdom (Address of principal exec

Akari Therapeutics Reports Full-Year 2022 Financial Results and Highlights

Exhibit 99.1 Akari Therapeutics Reports Full-Year 2022 Financial Results and Highlights · Development of lead asset nomacopan, a novel dual-mechanism inhibitor of complement C5 and leukotriene B4 (LTB4), is focused on two priority pipeline programs with potential to transform the complement inhibition category, as well as standard of care in a rare pediatric condition and mass market retinal disea

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of: May 2023 Commission file number: 001-36288

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of: May 2023 Commission file number: 001-36288 Akari Therapeutics, Plc (Translation of registrant’s name into English) 75/76 Wimpole Street London W1G 9RT United Kingdom (Address of principal exec

Exhibit 2.2

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 20-F (Mark One) ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of: April 2023 Commission file number: 001-362

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of: April 2023 Commission file number: 001-36288 Akari Therapeutics, Plc (Translation of registrant’s name into English) 75/76 Wimpole Street London W1G 9RT United Kingdom (Address of principal ex

Akari Therapeutics Granted 180-Day Extension by Nasdaq to Meet Minimum Bid Price Requirement

Exhibit 99.1 Akari Therapeutics Granted 180-Day Extension by Nasdaq to Meet Minimum Bid Price Requirement NEW YORK and LONDON, April 25, 2023 (GLOBE NEWSWIRE) — Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biotechnology company developing advanced therapies for autoimmune and inflammatory diseases, today announced that it has received notification from Nasdaq that Akari has been granted an

AKTX / Akari Therapeutics Plc - ADR / RPC Pharma Ltd - SC 13D/A Activist Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A Under the Securities Exchange Act of 1934 (Amendment No. 5)* Akari Therapeutics, Plc (Name of Issuer) Ordinary Shares, $0.0001 par value (Title of Class of Securities) 00972G108 (CUSIP Number) Gary Emmanuel, Esquire Greenberg Traurig, LLP One Vanderbilt Avenue New York, NY 10017 +1 212 801 9337 (Name, Address an

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of: March 2023 Commission file number: 001-362

6-K 1 tm2311144d16k.htm FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of: March 2023 Commission file number: 001-36288 Akari Therapeutics, Plc (Translation of registrant’s name into English) 75/76 Wimpole Street London W1G 9RT United

Akari Therapeutics, Plc Announces $4 Million Registered Direct Offering

Exhibit 99.1 Akari Therapeutics, Plc Announces $4 Million Registered Direct Offering · Offering includes 100% participation by Akari’s Board of Directors, including Akari President and CEO Rachelle Jacques · Offering includes accredited investors who have not previously participated · Definitive agreements include no warrants NEW YORK and LONDON, March 30, 2023 (GLOBE NEWSWIRE) - Akari Therapeutic

Form of Securities Purchase Agreement in connection with the March 2023 Registered Direct Offering (incorporated by reference to the exhibit previously filed with the Registrant’s Report on Form 6-K filed on March 31, 2023)

Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of March 30, 2023, between Akari Therapeutics, Plc, a public company with limited liability incorporated under the laws of England and Wales (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collective

26,666,667 American Depositary Shares Representing 2,666,666,700 Ordinary Shares

Filed pursuant to Rule 424(b)(5) Registration Statement No. 333-251673 PROSPECTUS SUPPLEMENT (To Prospectus dated December 31, 2020) 26,666,667 American Depositary Shares Representing 2,666,666,700 Ordinary Shares We are offering to certain investors 26,666,667 American Depository Shares, or ADSs, each representing 100 ordinary shares, par value $0.0001 per ordinary share. The ADSs, representing o

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of: March 2023 Commission file number: 001-362

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of: March 2023 Commission file number: 001-36288 Akari Therapeutics, Plc (Translation of registrant’s name into English) 75/76 Wimpole Street London W1G 9RT United Kingdom (Address of principal ex

Poland and U.K. Regulatory Authorities – URPL and MHRA – Approve Use of New, Higher-Yielding Manufacturing Process for Nomacopan in Pivotal Clinical Study

Exhibit 99.1 Poland and U.K. Regulatory Authorities – URPL and MHRA – Approve Use of New, Higher-Yielding Manufacturing Process for Nomacopan in Pivotal Clinical Study • Third generation drug substance manufacturing process increases the final yield of nomacopan by at least 5-fold, improving cost efficiencies in the continuing Phase 3 clinical trial of nomacopan in pediatric hematopoietic stem cel

Form 6-K, filed with the Securities and Exchange Commission on March 28, 2023

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of: March 2023 Commission file number: 001-36288 Akari Therapeutics, Plc (Translation of registrant’s name into English) 75/76 Wimpole Street London W1G 9RT United Kingdom (Address of principal ex

THE COMPANY

Exhibit 99.1 THE COMPANY Except as otherwise indicated herein or as the context otherwise requires, references to “Akari,” “we,” “us,” “our,” the “Company” and similar designations refer to Akari Therapeutics, PLC and its subsidiaries. When we refer to “you,” we mean prospective investors in the Company. Overview We are a clinical-stage biotechnology company focused on developing advanced therapie

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of: March 2023 Commission file number: 001-362

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of: March 2023 Commission file number: 001-36288 AKARI THERAPEUTICS, PLC (Translation of registrant’s name into English) 75/76 Wimpole Street London W1G 9RT United Kingdom (Address of principal ex

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of: February 2023 Commission file number: 001-

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of: February 2023 Commission file number: 001-36288 Akari Therapeutics, Plc (Translation of registrant’s name into English) 75/76 Wimpole Street London W1G 9RT United Kingdom (Address of principal

Akari Therapeutics Announces Presentation of a Case Study from Phase 3 Part A Clinical Trial of Nomacopan in Pediatric HSCT-TMA as a Late-Breaker at The Transplantation & Cellular Therapy Tandem Meetings

Exhibit 99.1 Akari Therapeutics Announces Presentation of a Case Study from Phase 3 Part A Clinical Trial of Nomacopan in Pediatric HSCT-TMA as a Late-Breaker at The Transplantation & Cellular Therapy Tandem Meetings NEW YORK and LONDON, Feb. 21, 2023 (GLOBE NEWSWIRE) - Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biotechnology company developing advanced therapies for autoimmune and infla

Akari Therapeutics Announces Pre-Clinical Development Progress Toward Potential IND on Long-Acting PAS-Nomacopan for Geographic Atrophy (GA)

Exhibit 99.1 Akari Therapeutics Announces Pre-Clinical Development Progress Toward Potential IND on Long-Acting PAS-Nomacopan for Geographic Atrophy (GA) · Akari is targeting an Investigational New Drug (IND) application submission to the U.S. Food and Drug Administration in the first half of 2024 · Composition of matter patent application filed on long-acting PAS-nomacopan versions, which, if gra

First 6-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of: February 2023 Commission file number: 001-36288 Akari Therapeutics, Plc (Translation of registrant’s name into English) 75/76 Wimpole Street London W1G 9RT United Kingdom (Address of principal